Literature DB >> 1289357

The activity of hydroxynaphthoquinones against Leishmania donovani.

S L Croft1, J Hogg, W E Gutteridge, A T Hudson, A W Randall.   

Abstract

The hydroxynaphthoquinones, buparvaquone, 250C80 and 56W82, showed high activity in vitro against Leishmania donovani amastigotes in mouse peritoneal macrophages, with ED50 values of 0.05, 2.95 and 13.82 microM, respectively. Fourteen other hydroxynaphthoquinones were tested, of which only 566C80 and 608C86 showed significant activity against amastigotes. Buparvaquone, 250C80 and 56W82 were also highly-active against cultured promastigotes. In a BALB/c mouse model, treatment with 100 mg/kg/day for five days with buparvaquone, 250C80 and 566C80 (atovaquone) reduced liver amastigote numbers by 60%, 22% and 30.5%, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1289357     DOI: 10.1093/jac/30.6.827

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

1.  Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.

Authors:  H W Murray; J Hariprashad
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

2.  An Antiparasitic Compound from the Medicines for Malaria Venture Pathogen Box Promotes Leishmania Tubulin Polymerization.

Authors:  Imran Ullah; Suraksha Gahalawat; Laela M Booshehri; Hanspeter Niederstrasser; Shreoshi Majumdar; Christopher Leija; James M Bradford; Bin Hu; Joseph M Ready; Dawn M Wetzel
Journal:  ACS Infect Dis       Date:  2020-07-20       Impact factor: 5.084

3.  Investigational drugs for visceral leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Investig Drugs       Date:  2014-11-20       Impact factor: 6.206

4.  Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.

Authors:  Joachim Müller; Adriana Aguado-Martínez; Luis-Miguel Ortega-Mora; Javier Moreno-Gonzalo; Ignacio Ferre; Matthew A Hulverson; Ryan Choi; Molly C McCloskey; Lynn K Barrett; Dustin J Maly; Kayode K Ojo; Wes Van Voorhis; Andrew Hemphill
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

5.  In vivo monitoring of intracellular ATP levels in Leishmania donovani promastigotes as a rapid method to screen drugs targeting bioenergetic metabolism.

Authors:  J R Luque-Ortega; O M Rivero-Lezcano; S L Croft; L Rivas
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

6.  Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.

Authors:  Thais Alves da Costa-Silva; Andrés Jimenez Galisteo; José Angelo Lauletta Lindoso; Leandro R S Barbosa; Andre Gustavo Tempone
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 7.  The anti-Leishmania potential of bioactive compounds derived from naphthoquinones and their possible applications. A systematic review of animal studies.

Authors:  Áquila Carolina Fernandes Herculano Ramos-Milaré; Jully Oyama; Letícia Sayuri Murase; João Vítor Perez Souza; Bárbara Silva Guedes; Daniele Stéfanie Sara Lopes Lera-Nonose; Mariana Terron Monich; Aline Ávila Brustolin; Izabel Galhardo Demarchi; Jorge Juarez Vieira Teixeira; Maria Valdrinez Campana Lonardoni
Journal:  Parasitol Res       Date:  2022-02-22       Impact factor: 2.289

8.  NADH-ubiquinone oxidoreductase activity in the kinetoplasts of the plant trypanosomatid Phytomonas serpens.

Authors:  Diego González-Halphen; Dmitri A Maslov
Journal:  Parasitol Res       Date:  2004-01-16       Impact factor: 2.289

9.  Targeting the Cytochrome bc1 Complex of Leishmania Parasites for Discovery of Novel Drugs.

Authors:  Diana Ortiz; Isaac Forquer; Jan Boitz; Radika Soysa; Carolyn Elya; Audrey Fulwiler; Aaron Nilsen; Tamsen Polley; Michael K Riscoe; Buddy Ullman; Scott M Landfear
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

10.  In Vitro and In Vivo Antifungal Activity of Buparvaquone against Sporothrix brasiliensis.

Authors:  Luana Pereira Borba-Santos; Thayná Lopes Barreto; Taissa Vila; Kung Darh Chi; Fabiana Dos Santos Monti; Marconi Rodrigues de Farias; Daniela S Alviano; Celuta S Alviano; Débora O Futuro; Vitor Ferreira; Wanderley de Souza; Kelly Ishida; Sonia Rozental
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.